In vitro-
Diagnostics and Bioanalysis
June 5 – 6 · 2013
Potsdam · GERMANY
Technology Forum
Supported by: Organized by:
In cooperation with:
5th Berlin-Brandenburg Technology Forum
Scientific Lectures
The latest trends in the deve-lopment of diagnostics
Exhibition
Showcasing products, services and technologies
Partnering
Pre-scheduled one-to-one meetings for companies and research institutes
Company Presentations
Presentations by innovative diagnostics companies
5th Berlin-Brandenburg Technology Forum
In vitro-
Diagnostics and Bioanalysis
Your partner for next Generation
in vitro
-Diagnostics
Being the largest life sciences-spot, more than 80
di-agnostics companies and a significant number of
well-known research institutes cover the full range of the
biotech and pharma value chain in the German Capital
Region.
The Berlin-Brandenburg region develops solutions for next gene-ration in vitro-diagnostics and bioanalysis, such as sensor-actor-molecules and autonomous biosensors, genome, proteome- and glycan-based multiplex analytics (microarray and bead technolo-gies) and metabolomics platforms for new biomarker strategies. Berlin-Brandenburg offers excellent conditions for implementing clinical validation studies. Being Germany’s most diversified hos-pital landscape with the Charité – Universitätsmedizin Berlin, it has access to patient cohorts of urban and rural populations of about 180 ethnicities, covering all medical indications. Custo-mers from research and industry have access to advanced bioban-king infrastructures.
June 5-6, 2013 · Potsdam 5th
Berlin-Brandenburg Technology
Forum “
In vitro-
Diagnostics and
Bioanalysis”
Facing the economical and medical challenges, new
biomarkers and innovative diagnostics become more
and more significant for the health care systems of the
future. As basis for individualized therapy decisions,
predictive testing is one of the key drivers for the next
generation of
in vitro-
diagnostics.
Berlin-Brandenburg covers the full range of the in vitro-diagnostics value chain, from biomarker identification to clinical validation, from manufacturers to service providers. A significant number of internationally renowned research institutes, the Charité, being the largest university clinic in Europe, and about 100 diagnostics companies contribute to being one of Germany´s hot spots for diagnostics development.
For many years now, the Berlin-Brandenburg Technology Forum on „In vitro-Diagnostics and Bioanalysis“ has been proving to be an excellent platform for initiating a sustainable dialogue bet-ween fundamental research, industrial development and clinical application. The 5th Technology Forum focuses on mass spectro-metry, protein arrays and aptamer-based sensors.
A specially designed partnering event for diagnostics companies and research institutes facilitates to meet new co-operation part-ners from Europe and aims at fostering and encouraging possible growth opportunities. Participants will have the opportunity to join a guided science tour in Potsdam on June 5th.
This June, the Technology Forum 2013 will be once again the place to be for discussing new trends and topics in the field of in vitro-diagnostics.
5th Berlin-Brandenburg Technology Forum
In vitro-
Diagnostics and Bioanalysis
5th Berlin-Brandenburg Technology Forum
In vitro-
Diagnostics and Bioanalysis
ProgrammeWednesday, June 5
13:00—14:30 Workshop
Impact of the future IVD regulation on SMEs in Europe—workshop with European experts organized by EDCA”
(by separate invitation)
15:00—17:00 Guided Science Tour to Potsdam-Golm Science Park
Leading international research from
biotechnology to gravitational physics, training for young researchers and research-based production combine to make this science park a location with extraordinary potential for innovation, guided tour of Fraunhofer Institute for Biomedical Engineering IBMT included, tour starts at conference venue.
15:00—17:30 EDCA Board Meeting
18:00—20:00 Welcome Reception (by separate invitation)
Welcome Address
Kai Bindseil · Healthcare Industries Cluster Manager Berlin-Brandenburg – HealthCapital
Biomarker strategy at Bayer AG
Ulrich Zügel · Bayer Pharma AG · Berlin · Germany
Life sciences in Canada: Changing paradigms in diagnostics and treatment
Pierre Bélanger · Sherbrooke Innopole Sherbrooke · Quebec
Programme
Thursday, June 6
Industrial Exhibition (9:00—17:00)
About 25 SME showcase their latest products and technologies
Partnering (9:00–17:00)
Welcome Addresses
09:00 Günter Stock · Healthcare Industries Cluster Spokesman Berlin-Brandenburg—HealthCapital and President of the Berlin-Brandenburg Academy of Sciences and Humanities (BBAW)
09:15 Basic research in Berlin-Brandenburg and diagnostics development
Peter Seeberger · Max Planck Institute of Colloids and Interfaces (MPIKG) · Berlin · Germany
09:30 Key Note
Mass spectrometry and its impact on next generation diagnostics development
Matthias Mann · Max Planck Institute of Biochemistry Martinsried · Germany
Session I
Technology Development
Chair: Frank Bier · Fraunhofer Insitute for Biomedical Engineering (IBMT)
10:10 Targeted proteomics and imaging mass spectrometry
Edwin de Pauw · Liège University · Liège · Belgium 10:40 Coffee
5th Berlin-Brandenburg Technology Forum
In vitro-
Diagnostics and Bioanalysis
11:00 DNA array to protein array technology (DAPA) for applications in proteomics
Ronny Schmidt · Babraham Institute · Cambridge United Kingdom
11:30 Design guidelines for the commercially successful production of lab-on-a-chip consumables
Ralf Himmelreich · Institut für Mikrotechnik Mainz GmbH Germany
12:00 The advantages of an aptamer based companion diagnostic strategy
Gregory Penner · NeoVentures Biotechnology Inc. London · Canada
12:30 Lunch
Session II
Biomarker and Clinical Research
Chair: Günter Peine · ZMDB
Rudolf Tauber · Charité – Universitätsmedizin Berlin 13:15 Mass cytometry based single cell analysis for
immunodiagnostics of the future
Andreas Thiel · BCRT/Charité Berlin · Germany
13:35 Metabolic biomarkers—an enabling new tool for the development of drugs and diagnostics
Philipp Schatz · Metanomics Health GmbH · Berlin Germany
13:55 Steroid analysis—clinical and research applications
Nils Krone · University of Birmingham · Birmingham United Kingdom
14:25 Quantitative mass spectrometry of peptides and proteins, a new era in clinical biomarker detection
Sylvain Lehmann · Universitaire de Montpellier Montpellier · France
14:55 Identification of autoantibody biomarkers for colon and prostate cancer screening assays using protein microarrays
Johanna Fuchs-Luna · AIT Austrian Institute of Technology GmbH · Vienna · Austria
15:25 Multiparametric protein detection in laboratory medicine—technology and applications
Masood Kamali-Moghaddam · Science for Life Laboratory Uppsala · Sweden
15:55 Expanding the quantitative targeted mass
spectrometry facility at the Necker-Enfants malades University Hospital: The upcoming change in clinical diagnosis
Sylvia Sanquer · Necker-Enfants malades University Hospital · Paris · France
16:15 Coffee
Session III
Industrial Development—Medical Application
Chair: Stefan von Senger und Etterlin · ZukunftsAgentur Brandenburg
16:35 International Company Presentations
17:35 End of programme
Guided City Tour (18:00—19:30)
This tour presents the cultural heart of Potsdam-Sanssouci palace and park, followed by dinner at an historical location guided tour is free of charge, dinner is to be paid individually.
Participation in the Technology Forum is free of charge. The fee for the partnering event amounts € 50.00 (incl. VAT). Prior registration is requested at
www.zmdb.de/technologyforum2013/ (Scientific Lectures and Guided Tours) www.b2match.eu/tech-forum5/ (Partnering Event)
Your benefits from the
Partnering Event:
k Showcase your profile to other participants of the event k Organize yourself individual pre-scheduled one-to-one
meetings with the help of a web-based online tool
k Meet potential business, technological or research partners
for future co-operation
k Develop partnerships leading to technological and
commercial collaboration
k Establish cross-border contacts for long-term business
relationships
Whom you will meet:
k Developers and producers of in vitro-diagnostics k Service providers
k Suppliers k Distributors k Research institutions
The earlier you submit your collaboration profile,
the more it will be noticed.
5th Berlin-Brandenburg Technology Forum
The European Diagnostic Clusters Alliance unites around 400 diagnostic companies in 7 EU countries and is fully supporting the event, making it a real European quality brand for SME-directed diagnostic partnering.
EDCA unites the strengths of Europe’s
diagnostics clusters for scientific
excellence and economic growth!
Main Objectives
»Facilitating the growth of European SMEs in medical diagnostics
»Promoting cooperations between diagnostic clusters
»Internationalizing of diagnostics development by European collaborative projects
Life Science Cluster Krakau PL
Lyonbiopôle Lyon FR
Nexxus East of Scotland Edinburgh GB
Oxfordshire Bioscience Network Oxford GB
UppsalaBio Uppsala SE
Contact
TSB Innovationsagentur Berlin GmbH
Zentrum für Molekulare Diagnostik und Bioanalytik (ZMDB) Dr. Günter Peine hahne@tsb-berlin.de www.zmdb.de Venue Schiffbauergasse · Schinkelhalle 14467 Potsdam · Germany Directions: www.schiffbauergasse.de/index.php?b=3&p=55 (English version available)
Further Information
www.zmdb.de/technologyforum2013/
The Center for Molecular Diagnostics and Bioanalysis (ZMDB) is a Flagship Project of the Joint Innovation Strategy Berlin-Brandenburg at the TSB Innovationsagentur Berlin GmbH. The ZMDB is funded by the states of Berlin and Brandenburg and co-financed by the European Regional Development Fund (ERDF) of the European Union. An investment in your future!
